D053220Chemicals & DrugsD12.776.543.750.073.600D12.776.543.750.705.852.760.396660.998746Receptors, TNF-Related Apoptosis-Inducing LigandFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson0.09854430.01427116research area of0.4019280.05715596subject area forWake Forest School of MedicineAnnetteHastieAnnette T. Hastie PhD36.09040200000000-80.2670059999999931Hastie, AnnetteProfessorRodolfoPascualRodolfo M. Pascual MD36.08959100000000-80.26859900000000836Pascual, RodolfoAssociate ProfessorLowellHartLowell L. Hart MD, FACP36.09103700000000-80.269096000000001965Hart, LowellAssociate ProfessorGaganDeepGagan Deep PhD36.09032400000000-80.266491000000001924Deep, GaganProfessor20721970Deep G, Gangar SC, Oberlies NH, Kroll DJ, Agarwal RMolecular carcinogenesisDeep G, Gangar SC, Oberlies NH, Kroll DJ, Agarwal R. Isosilybin A induces apoptosis in human prostate cancer cells via targeting Akt, NF-?B, and androgen receptor signaling. Mol Carcinog. 2010 Oct; 49(10):902-12.Mol Carcinog2010-10-01T00:00:002010Isosilybin A induces apoptosis in human prostate cancer cells via targeting Akt, NF-?B, and androgen receptor signaling.24403266Forero-Torres A, Infante JR, Waterhouse D, Wong L, Vickers S, Arrowsmith E, He AR, Hart L, Trent D, Wade J, Jin X, Wang Q, Austin T, Rosen M, Beckman R, von Roemeling R, Greenberg J, Saleh MCancer medicineForero-Torres A, Infante JR, Waterhouse D, Wong L, Vickers S, Arrowsmith E, He AR, Hart L, Trent D, Wade J, Jin X, Wang Q, Austin T, Rosen M, Beckman R, von Roemeling R, Greenberg J, Saleh M. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer. Cancer Med. 2013 Dec; 2(6):925-32.Cancer Med2013-10-25T00:00:002013Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.18922909Kim H, Morgan DE, Buchsbaum DJ, Zeng H, Grizzle WE, Warram JM, Stockard CR, McNally LR, Long JW, Sellers JC, Forero A, Zinn KRCancer researchKim H, Morgan DE, Buchsbaum DJ, Zeng H, Grizzle WE, Warram JM, Stockard CR, McNally LR, Long JW, Sellers JC, Forero A, Zinn KR. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res. 2008 Oct 15; 68(20):8369-76.Cancer Res2008-10-15T00:00:002008Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging.21211830Bevis KS, McNally LR, Sellers JC, Della Manna D, Londoño Joshi A, Amm H, Straughn JM, Buchsbaum DJGynecologic oncologyBevis KS, McNally LR, Sellers JC, Della Manna D, Londoño Joshi A, Amm H, Straughn JM, Buchsbaum DJ. Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. Gynecol Oncol. 2011 Apr; 121(1):193-9.Gynecol Oncol2011-01-05T00:00:002011Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.22Associate ProfessorInternal Medicine, Gerontology & Geriatric MedicineInternal Medicine, Hematology & OncologyInternal Medicine, Pulmonary, Critical Care, Allergy and Immunologic DiseasesUrologyPeterClarkPeter E. Clark MD3196Clark, PeterClinical Professor17666396Bin L, Thorburn J, Thomas LR, Clark PE, Humphreys R, Thorburn AThe Journal of biological chemistryBin L, Thorburn J, Thomas LR, Clark PE, Humphreys R, Thorburn A. Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. J Biol Chem. 2007 Sep 21; 282(38):28189-94.J Biol Chem2007-07-31T00:00:002007Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding.true1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Clinical ProfessorClinical Professor